Financing through the Sixth and Seventh Stock Acquisition Rights
First written in FY2021-Q2. 6 of 7 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2026-H1.
103 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「1 September 2025–28 February 2026 200 9,246,820 24 1,774,568 24 1,769,568 (Note) This increase resulted from the exercise of the Fifth Series Stock Acquisition Rights (stock options).」
The exercise of the Fifth Series Stock Acquisition Rights increased the number of shares by 200 during the current interim consolidated accounting period, and increased share capital and capital surplus by ¥24,000 each. - FY2022AdvancedAnnual report
「Number of convertible bonds with stock acquisition rights and other instruments with exercise price adjustment clauses exercised during the period (units) 2,180 Number of shares delivered upon exercise during the period (shares) 218,000 Average exercise price and other amounts related to exercises during the period (¥) 2,422 Funds raised through exercises during the period (¥ thousand) 527,992」
Regarding the Seventh Series Stock Acquisition Rights, 2,180 units were exercised during the consolidated fiscal year, resulting in the issuance of 218,000 shares and ¥528 million in funds raised. - FY2022-Q3AdvancedAnnual report
「During the nine-month period of the third quarter of the consolidated fiscal year, the issuance of new shares upon exercise of the Seventh Series Stock Acquisition Rights, issued through a third-party allotment with exercise price adjustment clauses, increased share capital and capital surplus by ¥265 million each.」
The issuance of new shares upon exercise of the Seventh Series Stock Acquisition Rights increased share capital and capital surplus by ¥265 million each. - FY2022-Q2AdvancedAnnual report
「Number of convertible bonds with stock acquisition rights and other instruments with exercise price adjustment clauses exercised during the quarterly accounting period (units) 2,180 Number of shares delivered upon exercise during the quarterly accounting period (shares) 218,000 Funds raised through exercises during the quarterly accounting period (¥ thousand) 527,992」
Regarding the Seventh Series Stock Acquisition Rights, 2,180 units were exercised during the quarter, resulting in the issuance of 218,000 shares and ¥528 million in funds raised. - FY2022-Q1AdvancedAnnual report
「Between the end of the first-quarter consolidated accounting period and 31 December 2021, some of the Seventh Series Stock Acquisition Rights, issued through a third-party allotment with exercise price adjustment clauses, were exercised. The details of these exercises are as follows.」
Regarding the Seventh Series Stock Acquisition Rights, 500 units were exercised, resulting in increases of 50,000 common shares, ¥61 million in share capital and ¥61 million in capital surplus. - FY2021-Q3AdvancedAnnual report
「Number of convertible bonds with stock acquisition rights and other instruments with exercise price adjustment clauses exercised during the quarterly accounting period (units) 2,150 Number of shares delivered upon exercise during the quarterly accounting period (shares) 215,000 Funds raised through exercises during the quarterly accounting period (¥ thousand) 535,650 Cumulative funds raised through exercises of convertible bonds with stock acquisition rights and other instruments with exercise price adjustment clauses as of the end of the quarterly accounting period (¥ thousand) 1,259,150」
Regarding the Sixth Series Stock Acquisition Rights, 215,000 shares were issued and ¥536 million was raised during the third quarter. Cumulatively, the figures were 509,000 shares and ¥1,259 million. - FY2021-Q2First statedAnnual report
「Number of shares delivered upon exercise during the quarterly accounting period (shares) 294,000 Funds raised through exercises during the quarterly accounting period (¥ thousand) 723,500」
The company issued the Sixth and Seventh Series Stock Acquisition Rights in February 2021. During the quarter, 2,940 Sixth Series rights were exercised, resulting in the issuance of 294,000 shares and ¥724 million in funds raised. The Seventh Series rights are structured so that the initial suspension designation will lapse if an M&A transaction of ¥100 million or more or an urgent funding need arises, among other circumstances.